Thread Content
In non-GMP industries, when equipment breaks down, the process of repairing it, testing it to ensure it works properly, and resuming production is straightforward. But in the pharmaceutical industry, for the same thing, the logic is completely different—the goal of equipment maintenance is not simply to fix it, but to obtain QA approval. Why? Because the maintenance of pharmaceutical equipment is directly related to drug quality and patient safety. Has equipment maintenance introduced new pollution risks? Has it damaged the device’s “verification status”? The answers to these questions must be provided by QA. Maintenance release: The fundamental difference between general EAM and pharmaceutical EAM. In equipment maintenance release within the general manufacturing industry, the core principle is based on technical logic: fault repair → successful functional testing → approval by the technical supervisor → resumption of operation. The standards are defined by the technical parameters of the equipment and safety production procedures. The approval process for equipment maintenance in the pharmaceutical industry is based on quality principles: maintenance is completed → the impact on the equipment’s ‘confirmed state’ and product quality is assessed → the equipment is cleaned, tested, and its state is re-confirmed to prove that it is back to normal → QA approves its release. The standards are defined by both GMP regulations and product quality standards. This difference stems from the strict requirements set by GMP regulations: Article 81 of GMP specifies that equipment that has been modified or undergoes major repairs must be re-validated before it can be used in production. According to Appendix 1 of the PIC/S GMP guidelines, any maintenance work must be approved before the equipment can be put back into use. The requirements outlined in the GMP appendixes for sterile drugs dictate that a risk assessment must be conducted throughout the process of external repairs on sterile equipment, with all related documentation to be kept on file. The definition of “meeting the requirements for equipment release” in the pharmaceutical industry is much stricter than simply “the equipment being able to operate”. Sensong Mo-EAMaster: A closed-loop maintenance management system designed for pharmaceutical compliance. Sensong Mo-EAMaster is fully aligned with the GMP compliance requirements of the pharmaceutical industry, and it establishes a comprehensive compliance-based maintenance management system with QA quality verification after maintenance as its core element. A closed-loop system for defining responsibilities among the three parties, eliminating the notion that repairs are complete once they’re finished. The system divides the entire equipment repair process into three distinct responsibility areas, ensuring clear roles and full traceability throughout the process: The using department is responsible for submitting repair requests and conducting on-site inspections, while also keeping track of equipment performance and any faults, as well as retaining all relevant records. The engineering department handles the actual repair work, with specialized approval processes in place for tasks such as working in hazardous environments or at heights; an internal inspection is carried out after the repairs are completed. The Quality Assurance department conducts a dual-layer risk assessment to determine whether the repairs have caused any quality issues (and initiates investigations if necessary); for major repairs or those involving critical sterile equipment, a re-verification process is mandatory before the equipment can be approved for use again. QA’s approval after repairs represents the “final checkpoint” for compliance with GMP standards. SensoMo-EAMaster strictly adheres to regulatory requirements, standardizing the compliance process for repairs: from completion of repairs, to quality risk assessment, to cleaning and condition verification, up to final QA approval before the equipment can be put back into production. Once a work order is forwarded to QA, the system automatically activates a dual-risk assessment mechanism: for emergency, unplanned repairs involving critical assets such as sterile production lines and key process equipment, a sterile risk assessment must be conducted and documented to prevent the risk of drug contamination ； Major equipment overhauls and modifications are subject to mandatory reconfirmation/reverification processes to prevent the deployment of non-compliant equipment. QA holds the final approval authority, which is a fundamental requirement of GMP. Full-process traceability is available, enabling easy handling of GMP audit requests, task assignments, approvals for special operations, maintenance inspections, deviation assessments, verification and validation, as well as QA releases – with all processes documented online, and work orders, logs, and compliance reports interconnected and automatically archived. The system has been validated in full compliance with GAMP5; it features built-in audit tracking, supports electronic signatures and role-based access control, and meets the requirements of FDA 21 CFR Part 11. Digital records can be accessed and verified at any time, effectively addressing the problems associated with traditional paper records, such as easy loss, difficulty in tracking, and cumbersome correction processes. Compliance is not a cost, but an ability; EAM is concerned with whether equipment is repaired on time” ； The pharmaceutical industry is concerned about whether the equipment remains in a validated state after maintenance. The former is an operation and maintenance event record, while the latter is a proof of quality status. Compliance is the direction, while digitalization is the means. Compliance without digital and intelligent support is inefficient and unsustainable ； Digital transformation without compliance guidance is dangerous and unacceptable. The value of Sensoon Mo-EAMaster lies in transforming compliance from a “cost” into a “capability”.